دورية أكاديمية
Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registry.
| العنوان: | Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registry. |
|---|---|
| المؤلفون: | van den Reek JM; Department of Dermatology, Radboud university medical center, Nijmegen, the Netherlands., Tummers M, Zweegers J, Seyger MM, van Lümig PP, Driessen RJ, van de Kerkhof PC, Kievit W, de Jong EM |
| المصدر: | Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2015 Mar; Vol. 29 (3), pp. 560-5. Date of Electronic Publication: 2014 Aug 04. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9216037 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-3083 (Electronic) Linking ISSN: 09269959 NLM ISO Abbreviation: J Eur Acad Dermatol Venereol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Oxford : Wiley-Blackwell Original Publication: Amsterdam ; New York : Elsevier Science Publishers, c1992- |
| مواضيع طبية MeSH: | Adalimumab/*therapeutic use , Anti-Inflammatory Agents/*therapeutic use , Psoriasis/*drug therapy, Adult ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies |
| مستخلص: | Background: Drug survival is an indicator for treatment success; insight in predictors associated with drug survival is important. Objectives (i): To analyse the long-term drug survival for adalimumab in patients with psoriasis treated in daily practice and (II) to identify predictors of prolonged drug survival for adalimumab split for different reasons of discontinuation. Methods: Data were extracted from a prospective psoriasis cohort and analysed using Kaplan-Meier survival curves split for reasons of discontinuation. Baseline predictors associated with longer drug survival were identified using multivariate Cox-regression analysis. Results: One hundred and sixteen patients were included with a total of 208 patient-years. Overall drug survival was 76% after 1 year and 52% after 4.5 years. In patients who stopped due to ineffectiveness, longer drug survival was associated with the absence of specific comorbidities (P = 0.03). In patients who stopped due to side-effects, longer drug survival was associated with male gender (P = 0.02). Conclusions: Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation. Strong, specific predictors can lead to patient-tailored treatment. (© 2014 European Academy of Dermatology and Venereology.) |
| المشرفين على المادة: | 0 (Anti-Inflammatory Agents) FYS6T7F842 (Adalimumab) |
| تواريخ الأحداث: | Date Created: 20140805 Date Completed: 20151214 Latest Revision: 20150216 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1111/jdv.12636 |
| PMID: | 25088451 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1468-3083 |
|---|---|
| DOI: | 10.1111/jdv.12636 |